Is GPCR Overvalued?

GPCR is now in the Fair zone, suggesting that GPCR current forward PE ratio of -32.71 is considered Fair compare with the five-year average of -39.28.
P/E
EV/EBITDA
P/S
P/B
bubble
P/E

GPCR Competitors Valuation Multiple

P/E
EV/EBITDA
P/S

P/E Multiple

Earnings Growth
Market Cap
stocks logo
GPCR.O
Structure Therapeutics Inc
loss
Average P/E: 10.21
-20.34%
1.23B
stocks logo
ANIP.O
ANI Pharmaceuticals Inc
10.21
-1612.78%
1.38B
stocks logo
ARVN.O
Arvinas Inc
loss
75.24%
621.01M
stocks logo
NVAX.O
Novavax Inc
loss
64.88%
1.30B
stocks logo
IOVA.O
Iovance Biotherapeutics Inc
loss
43.30%
1.25B
stocks logo
CLDX.O
Celldex Therapeutics Inc
loss
1.41B

GPCR Revenue Breakdown & PS Ratio Relation

Currency:USD
By Business
By Region
Composition ()
Name
Revenue
Percentage

GPCR FAQs

Is GPCR currently overvalued based on its P/E ratio?

According to the provided data, GPCR's 5-year historical average forward P/E ratio is -39.28. GPCR forward P/E ratio is -32.71, which is categorized as Fair.

What is the significance of the EV/EBITDA ratio for GPCR?

What are the key indicators to watch for GPCR's financial performance?

GPCR PE Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
Fair
5Y Average PE
-39.28
Current PE
-32.71
Overvalued PE
-27.10
Undervalued PE
-51.45

GPCR EV/EBITDA Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
Fair
5Y Average EV
-4.40
Current EV
0.00
Overvalued EV
0.05
Undervalued EV
-8.85

GPCR P/S Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
Fair
5Y Average PS
0.63
Current PS
0.00
Overvalued PS
4.76
Undervalued PS
-3.50

Free Financial AI Agent for Investment

Ask any investment related question and get answer instantly

At what price is GPCR undervalued?Is GPCR overvalued compared to its competitors?